CorMatrix launches FDA IDE Cor Tricuspid ECM cardiac valve trial

CorMatrix Cardiovascular said today that it launched a trial of its Cor Tricuspid ECM cardiac valve intended for treating adults with endocarditis and pediatric patients with congenital heart valve disease, adding that the first patient in the trial has already been treated. The first procedure in the trial took place at the Francicscan Health Heart Center by a team led by Dr. Marc Gerdisch, Atlanta-based CorMatrix said. The patient, who was suffering from endocarditis, has returned home and is recovering well, the company added. “This first FDA study enrollment is a substantial step toward patients avoiding synthetic or animal tissue replacement valves, by having the opportunity to regrow their own tissue. We have been using CorMatrix for eight years with exceptional success in reconstructing complex structures of the heart and blood vessels. Given the remarkable adaptability and regenerative properties of CorMatrix, this new valve structure will have a dramatic effect on surgery for tricuspid valve pathology, especially for younger patients. Furthermore, it serves as a platform for engineering other heart valves,” Dr. Gerdisch said in a prepared statement. CorMatrix touts its Cor Tricuspid ECM cardiac valve as the first cardiac valve of its kind to be composed of an extracellular matrix, and said that its CorMatrix ECM material has been used in more than 220,000 cardiac implants to date. “This important step for our patients and CorMatrix, to create a val...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiac Implants Cardiovascular Clinical Trials Featured Replacement Heart Valves CorMatrix Cardiovascular Inc. Source Type: news